



PRESS RELEASE FOR IMMEDIATE USE

Dechra Veterinary Products enters into an Exclusive North American Sales and Marketing Partnership with Kane Biotech for Patented Dental and Dermatology Technology

Dechra Veterinary Products is pleased to announce a North American partnership with Kane Biotech, a Canadian based technology company engaged in the development of products that prevent and remove microbial biofilms. The initial joint project will be the development and launch of a premium line of veterinary exclusive oral health products designed to fight plaque and tartar utilizing Kane's patented and patent-pending biofilm and mineral chelation technology.

"With periodontal disease being a leading contributor to health problems in pets, we are eager to expand our dental range with clinically-proven, innovative technology that is safe and efficacious. We are pleased to partner with Kane Biotech to further develop their technology in the veterinary market. Kane's intellectual property has received positive feedback from many Key Opinion Leaders," says Mike Eldred, President of Dechra North America.

Mark Ahrens-Townsend, CEO of Kane commented on the partnership with Dechra, "We are pleased to have partnered with Dechra, a leader in the veterinary dental and dermatology markets. In a controlled clinical study in sixty healthy dogs, the calculus score for the treated dogs was 25.4% lower than the control group. The study demonstrated our technology is effective in preventing dental calculus. We look forward to a long-term strategic partnership with Dechra."

In addition to the dental applications, Dechra and Kane will further partner to develop new dermatological therapies employing this patented and patent-pending biofilm technology and dispersin-B, another patented molecule.

The Kane oral health product range is currently being sold under the brand StrixNB. Dechra expects to transition these dental products under a new Dechra tradename over the coming months.

Contact:

Paul Ray
General Manager
Dechra Veterinary Products, Canada
Paul.Ray@Dechra.com

Ranbir Padwal
National Sales Manager
Dechra Veterinary Products, Canada
Ranbir.Padwal@Dechra.com

About Dechra

Dechra is an international business specializing in veterinary pharmaceuticals and related products. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. The majority of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information, please visit: www.dechra.ca.

Stock Code: Full Listing (Pharmaceuticals): DPH

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

Forward Looking Statement

This document may contain certain forward-looking statements. The forward-looking statements reflect the knowledge and information available to the Company during the preparation and up to the publication of this document. By their very nature, these statements depend upon circumstances and relate to events that may occur in the future thereby involve a degree of uncertainty. Therefore, nothing in this document should be construed as a profit forecast by the Company.

Market Abuse Regulation (MAR)

The information contained within this announcement may contain inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

For more information, please visit www.dechra.ca or call (855) 332-9334.

About Kane Biotech

Kane Biotech is a biotechnology company engaged in the research and development of technologies that prevent and remove microbial biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, antimicrobials, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to numerous human and animal health related problems such as wound care infections, recurrent urinary tract infections, tooth decay, medical device associated and hospital-acquired infections, as well as foodborne bacterial infections. According to the United States National Institutes of Health, biofilms are estimated to be responsible for 80% of all human bacterial infections which cost individuals, industry, governments and hospitals billions of dollars each year. As such, there is significant interest in safe and effective products that can combat the biofilm problem. Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. The Corporation has evidence that these technologies have the potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.